Can a cholesterol drug tame inflammation in diabetes? small study investigates

NCT ID NCT03829046

Completed Knowledge-focused Sponsor: Robert Rosenson Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 4 trial looked at how evolocumab (Repatha), a cholesterol-lowering drug, affects markers of inflammation and blood clotting in 41 people with type 2 diabetes and heart disease. Participants received either evolocumab or a placebo injection every 4 weeks for 12 weeks. The goal was to understand the drug's short-term effects on these biological markers to inform future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: evolocumab (Repatha)
What this could lead to: If successful, this could help design a larger trial to see if evolocumab improves blood vessel function in people with type 2 diabetes.
What could go wrong: This was a small, early-phase study focused on biological markers, not on patient outcomes. It may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC VASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis coronary microvascular disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC VASCULAR DISEASE MICROVASCULAR DYSFUNCTION TYPE2 DIABETES

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
St. Michael's - University of Toronto

Toronto, Ontario, M5B1W8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.